skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

“Although approximately 70% of people with epilepsy respond to treatment, the number of prevalent cases of active epilepsy remains high.”

Epilepsy is a disorder of the brain characterized by recurrent, unprovoked seizures, and is the oldest and most common chronic neurologic disorder. The majority of idiopathic epilepsy is found among young children, and secondary epilepsy associated with comorbidities is common among older populations. People with epilepsy respond to treatment with antiepileptic drugs approximately 70% of the time. The population of people with active epilepsy represents people who have been diagnosed with epilepsy and continue to have seizures or a need for treatment.

Datamonitor Healthcare estimates that in 2015, there were 4.6 million diagnosed prevalent cases of active epilepsy in the US, Japan, and five major EU markets. By 2035, this is forecasted to increase to approximately 5.0 million diagnosed prevalent cases. The overall increase in the number of diagnosed prevalent cases is influenced by the dynamics of the forecasted demographic changes in the markets of interest. The negative growth in the number of diagnosed prevalent cases in some countries is primarily attributable to the decrease in overall United Nations population projections for those countries over the forecast period.

Trend in diagnosed prevalent cases of active epilepsy in the US, Japan, and five major EU markets, by country, 2015–35

Corresponding report – Epidemiology: Epilepsy

 

 

Datamonitor Healthcare’s Epidemiology: Epilepsy module provides a detailed epidemiological analysis of the diagnosed prevalence of active epilepsy across the US, Japan, and five major EU markets. This includes a 20-year diagnosed prevalence forecast (2015–35) for active epilepsy segmented by age and gender, as well as an interactive epidemiology datapack that incorporates treatment data from Datamonitor Healthcare’s proprietary epilepsy research survey.